暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
IDXX240517C540000
- 2.40
- -1.40-36.84%
延时15分钟行情收盘价 05/17 15:59 (美东)
2.40最高价1.05最低价
1.05今开3.80昨收2张成交量0张未平仓合约数540.00行权价345.00成交额129.67%隐含波动率0.17%溢价2024/05/17到期日3.45内在价值100合约乘数-2天距到期日0.00时间价值100合约规模美式期权类型0.7325Delta0.0585Gamma124.22杠杆倍数-40.4637Theta0.0003Rho90.99有效杠杆0.0143Vega
分时
- 5日
- 日K
新闻
Form 144 | 爱德士(IDXX.US)董事拟出售200股股份，价值约10.82万美元
根据美国证券交易委员会（SEC）美东时间5月17日披露的文件，$爱德士(IDXX.US)$董事Claflin Bruce L.拟于5月17日出售200股普通股股份，总市值约10.82万美元。 图片来源：SEC公告 什么是Form 144？《1933年美国证券法》Rule 144规定：上市公司中关联方（上市公司持股10%以上的大股东、公司高管及董事成员）以及从关联方中获得股票（这一类股票属于
标普500指数、纳斯达克100指数、道琼斯指数在不可阻挡的牛市反弹中创下历史新高
标准普尔500指数、纳斯达克100指数和道琼斯工业平均指数周三均创下历史新高，这得益于一份温和的通胀报告，该报告提振了看涨投资者的风险情绪。
IDEXX 实验室将出席Stifel会议并宣布2024年投资者日
宠物医疗创新领域的全球领导者IDEXX Laboratories, Inc.（纳斯达克股票代码：IDXX）今天宣布，执行副总裁兼首席财务官布莱恩·麦坚和执行副总裁迈克尔·莱恩
摩根士丹利维持IDEXX实验室增持
摩根士丹利维持IDEXX实验室增持
摩根士丹利将IDEXX实验室的目标股价从620美元调整至596美元
Capital IQ调查的分析师表示，IDEXX Laboratories（IDXX）的平均跑赢大盘评级，目标股价区间为400美元至641美元。价格：500.30，涨幅：-2.72，变动百分比：-0.54
IDEXX 实验室公司（纳斯达克股票代码：IDXX）的估值可能被低估吗？
让我们来谈谈广受欢迎的IDEXX实验室有限公司（纳斯达克股票代码：IDXX）。最近几个月，该公司的股票在纳斯达克证券交易所的股价出现了大幅波动，升至577美元和f的高位
评论
$爱德士(IDXX.US$ 👀 Here's How Much You Would Have Made Owning
IDEXX Laboratories Stock In The Last 15 Years!
IDEXX Laboratories Stock In The Last 15 Years!
The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
Long-term performance of IDEXX shows positive returns despite recent downturn. Market caution and strong momentum warrant closer scrutiny. Nonetheless, investors should note the existent 2 warning signs.
Comment:
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...
阅读更多